# Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

> **NCT02834286** · PHASE2 · UNKNOWN · sponsor: **Hospital Universitario Dr. Jose E. Gonzalez** · enrollment: 15 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Eltrombopag
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02834286
- **Lead sponsor:** Hospital Universitario Dr. Jose E. Gonzalez
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2017-03
- **Final completion:** 2017-09
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2016-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02834286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02834286, "Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02834286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*